The US Food and Drug Administration approved Foundayo, a new once-daily pill for obesity treatment, on Wednesday. Eli Lilly, the manufacturer, also produces the weight-loss injection Zepbound. The approval positions Foundayo as the second obesity pill cleared by the FDA.
The FDA's approval came on Wednesday for Foundayo, developed by Eli Lilly as a once-daily oral medication targeting obesity. This decision allows the pill to enter the market amid growing demand for non-injectable weight-loss options. Eli Lilly, known for its injectable Zepbound, now expands its portfolio with this GLP-1-based pill, as first reported by WIRED. Foundayo joins a select group of obesity treatments, becoming only the second pill approved by the regulator for this purpose. Previously, Novo Nordisk received clearance for an oral version of its Wegovy injection. Industry observers note the competition will intensify between Eli Lilly and Novo Nordisk in the booming GLP-1 drug sector, though specific launch dates and pricing for Foundayo remain undisclosed.
